14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ADUS vs ARDT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ARDT Overall Winner
6-Pillar Tally: ADUS 2 – 3 ARDT (1 Tie)
Matrix Metrics: ADUS 7 – 3 ARDT
As of Nov 20, 2026, Ardent Health, Inc. (ARDT) is the stronger overall head-to-head candidate over Addus HomeCare Corp. (ADUS) in the Tradestie Institutional Equity Comparison Engine, winning 3–7 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). ADUS carries a Unified Composite Score of 59.0/100 (HOLD) at $122.50 (16.1x Forward P/E, 10.4% operating margin), whereas ARDT carries 40.2/100 (SELL) at $15.08 (10.9x Forward P/E, 5.1% operating margin).
Composite vs. Pillar Nuance: While ADUS currently prints a higher short-term Unified Composite Score (59.0/100 HOLD vs. ARDT 40.2/100 SELL), ARDT captures the overall institutional head-to-head verdict (3–7 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (5.1% vs. 10.4% operating margin) and revenue trajectory (+3.1% vs. +7.0% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ADUS vs ARDT. Trailing 12-month operating profitability (ADUS 10.4% vs ARDT 5.1%) and valuation multiples (ADUS 16.1x vs ARDT 10.9x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Care Facilities value chain with $2.0B market capitalization and 5.1% operating margin.
OpEx & R&D Reinvestment54.0% of Rev ($3.49B)
90D Engineering Disclosures0 Published
Investor FAQ ADUS vs ARDT Key Questions & Quantitative Answers
As of Nov 20, 2026, Ardent Health, Inc. (ARDT) is the stronger overall head-to-head candidate over Addus HomeCare Corp. (ADUS) in the Tradestie Institutional Equity Comparison Engine, winning 3–7 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). ADUS carries a Unified Composite Score of 59.0/100 (HOLD) at $122.50 (16.1x Forward P/E, 10.4% operating margin), whereas ARDT carries 40.2/100 (SELL) at $15.08 (10.9x Forward P/E, 5.1% operating margin). Composite vs. Pillar Nuance: While ADUS currently prints a higher short-term Unified Composite Score (59.0/100 HOLD vs. ARDT 40.2/100 SELL), ARDT captures the overall institutional head-to-head verdict (3–7 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (5.1% vs. 10.4% operating margin) and revenue trajectory (+3.1% vs. +7.0% YoY).
ADUS leads the Growth & Scale pillar: ADUS posts +7.0% YoY revenue growth and +24.2% YoY earnings growth on $1.50B TTM revenue (32.3% gross margin, 10.4% operating margin), compared with ARDT at +3.1% YoY revenue growth and -77.1% YoY earnings growth on $6.45B TTM revenue (59.1% gross margin, 5.1% operating margin). On trailing 12-month operating scale, ADUS generates $1.50B in USD-normalized revenue versus $6.45B for ARDT. In operating R&D and SG&A reinvestment, ADUS deploys 21.9% of Rev ($329M) (0 90-day corporate R&D disclosures) versus 54.0% of Rev ($3.49B) (0 disclosures) for ARDT.
ARDT screens cheaper on headline valuation multiples. ADUS trades at 16.1x Forward P/E, 20.1x Trailing P/E, 1.05x PEG, and 1.5x EV/Revenue (11.5% EBITDA margin), whereas ARDT trades at 10.9x Forward P/E, 14.1x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (7.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ADUS (10.0% ROE) versus ARDT (13.5% ROE) capital efficiency.
In options market volatility and institutional positioning, ADUS carries 21.9% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.07β · 21% Vol realized risk). By comparison, ARDT carries 53.1% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.01β · 115% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.